BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

CSL Limited Completes Acquisition Of Aventis Behring To Create ZLB Behring


10/19/2005 5:10:39 PM

MELBOURNE, Australia, March 31 /PRNewswire/ -- CSL Limited today announced the completion on March 31, 2004 of its acquisition of global plasma therapeutics business, Aventis Behring from Aventis SA.

CSL will combine Aventis Behring with ZLB Bioplasma to create a new business, ZLB Behring. With ZLB Behring and CSL Bioplasma, CSL is now positioned as a world leader in plasma therapeutics.

CSL Managing Director, Dr Brian McNamee said "Today's plasma products industry demands a broad portfolio of quality products, an innovative R&D pipeline, an efficient high yield production operation, the ability to balance market demands and outputs and a global marketing effort".

"Within the CSL Group, ZLB Behring is well positioned to realize all of these key attributes", said Dr McNamee.

Peter Turner, currently head of ZLB Bioplasma, will be President of ZLB Behring which will be headquartered in King of Prussia, Pennsylvania, USA. CSL Limited will remain headquartered in Melbourne, Australia.

Mr Turner said "The combination of ZLB Bioplasma's IVIG production capabilities with Aventis Behring's coagulation products, haemophilia expertise and specialty products coupled with global marketing reach continues to represent a compelling opportunity".

Dr. McNamee said "Our integration planning during the pre-closing period has continued to give us confidence that the acquisition will deliver enhanced economic returns. This is consistent with the information provided during our recent fundraising for the acquisition".

"We have a clear plan for integration and talented people in the combined business to make the changes required to achieve strong leadership in a competitive market", said Dr McNamee

In order to provide additional time to finalise the financials of the combined entity for the first time, the company's full year result announcement has been changed from 18 August to 26 August 2004.

CSL Limited

CONTACT: Australia Media, Tim Duncan of Hintons and Associates,+61-3-9600-1979; or US Media, Kim Cayz, +1-610-878-4822, orkim.cayz@aventis.com; or Europe Media, Gina Duscher, +49-6421-39-4222, orgina.duscher@aventis.com, both of ZLB Behring; or US Trade Media, Rum Ekhtiar,rum@fischerhealth.com, or Jill Hoffman, jhoffman@fischerhealth.com, both ofFischerHealth, A Porter Novelli Company, +1-310-577-7870; or Investors, MarkDehring of CSL Investor Relations Manager, +61-3-9389-2818, ormark.dehring@csl.com.au


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->